Program
Ranibizumab
Also written as “ranibizumab”, “Ranibizumab 0.5 mg” and “rhuFab V2 (ranibizumab)”.
Its studies are mostly in Macular Degeneration · Macular Edema · Choroidal Neovascularization · Retinal Vein Occlusion · Vision Disorders, led by 16 companies.
Drug pageRanibizumab: every studyMany companies study it; this page follows only the 98 they lead. All 351 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartisits history only | 560 open or running | phase 4since Jul 19, 2007 | Jan 11, 2006 | none ahead |
| Hoffmann-La Rocheits history only | 244 open or running | phase 4since Jan 13, 2011 | Mar 24, 2003 | Feb 4, 2027phase 3 · NCT04657289 |
| AbbVieits history only | 31 open or running | phase 4since Aug 31, 2011 | Oct 16, 2008 | Jul 2031phase 2 · NCT05210803 |
| Samsung Bioepisits history only | 20 open or running | phase 2since Dec 11, 2023 | Dec 11, 2023 | none ahead |
| Santen Pharmaceuticalits history only | 20 open or running | phase 2since Oct 1, 2008 | Oct 1, 2008 | none ahead |
| AO GENERIUMits history only | 11 open or running | phase 3since Nov 30, 2020 | Nov 30, 2020 | none ahead |
| bioeq-gmbhits history only | 10 open or running | phase 3since Nov 19, 2015 | Nov 19, 2015 | none ahead |
| Cynosure Lutronicits history only | 10 open or running | phase 4since Nov 27, 2018 | Nov 27, 2018 | none ahead |
| Formycon | 10 open or running | phase 4since Nov 25, 2024 | Nov 25, 2024 | none ahead |
| Incepta Pharmaceuticalsits history only | 10 open or running | phase 3since Mar 5, 2024 | Mar 5, 2024 | none ahead |
| oraya-therapeutics-incits history only | 10 open or running | no phasesince Jan 24, 2012 | Jan 24, 2012 | none ahead |
| pfenex-incits history only | 10 open or running | phase 2since Apr 17, 2014 | Apr 17, 2014 | none ahead |
| Qilu Pharmaceuticalits history only | 10 open or running | phase 1since Oct 12, 2017 | Oct 12, 2017 | none ahead |
| qlt-incits history only | 10 open or running | phase 2since Jun 25, 2007 | Jun 25, 2007 | none ahead |
| shanghai-biomabs-pharmaceutical-co-ltdits history only | 10 open or running | phase 1since May 6, 2021 | May 6, 2021 | none ahead |
| xbrane-biopharma-abits history only | 10 open or running | phase 3since Jan 8, 2019 | Jan 8, 2019 | none ahead |
Also a collaborator on its studies: REGENXBIO, Stada Arzneimittel and MacuSight.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Formycon only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 25, 2024First study: phase 4 study in Macular DegenerationFirst studyNCT06708624 · 31 enrolled · United States
TargetBeta
“A second-generation, recombinant humanized IgG1 kappa monoclonal antibody fragment directed against human vascular endothelial growth factor (VEGF) alpha”NCIt, by rule
“Vascular endothelial growth factor A inhibitor”ChEMBL 37, by rule
Other programs on VEGFA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Bevacizumabrule | Hoffmann-La Roche | phase 4 | 250 |
| afliberceptrule | Regeneron Pharmaceuticals | phase 4 | 89 |
| faricimabrule | Hoffmann-La Roche | phase 4 | 17 |
| ivonescimabrule | Akeso | phase 3 | 48 |
| pumitamig | BioNTech | phase 3 | 34 |
| tivunatamig | Pfizer | phase 3 | 15 |
| suvemcitugrule | Simcere Pharmaceutical Group | phase 3 | 6 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14rule | Sinocelltech Group | phase 3 | 2 |
| surabgene lomparvovec | AbbVie | phase 3 | 2 |
| ABBV-1480 | RemeGen | phase 3 | 2 |
| HLX37 | Fosun Pharma | phase 3 | 2 |
| Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001rule | Sichuan Kelun Pharmaceutical | phase 2 | 4 |
Studies
The one study Formycon leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06708624Macular Degeneration · United States | 4 | Completed | Aug 8, 2024 | 31 |
How it is read
Names in the registry
- “Ranibizumab”, 40 entries
- “ranibizumab”, 18 entries
- “Ranibizumab 0.5 mg”, 11 entries
- “rhuFab V2 (ranibizumab)”, 6 entries
- “Ranibizumab 0.5mg”, 4 entries
Conditions, from the studies’ own filings
- Macular Degeneration, 41 studies
- Macular Edema, 22 studies
- Choroidal Neovascularization, 15 studies
- Retinal Vein Occlusion, 7 studies
- Vision Disorders, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.